CALT

Calliditas Therapeutics AB American Depositary Shares

CALT

Market cap $1.08B

Delisted

CALT was delisted on the 20th of September, 2024.

Back to rankings

About: Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Employees: 222

Healthcare Drug Manufacturers - General

Financial journalist opinion

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg.

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions.

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript

Calliditas Therapeutics AB (publ) (NASDAQ:CALT ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Renée Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO Conference Call Participants Operator Welcome to Calliditas Q2 2024 Report. [Operator Instructions] And there will be no Q&A session after the presentation.

Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript

Calliditas Interim Report January to June 2024

STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.

Calliditas Interim Report January to June 2024

Number of shares and votes in Calliditas Therapeutics

STOCKHOLM , July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board of Directors program LTIP 2021. As of today, the total number of outstanding shares in Calliditas Therapeutics AB (publ) amounts to 59,941,465 ordinary shares.

Number of shares and votes in Calliditas Therapeutics

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atrion Corporation (NASDAQ: ATRI)'s sale to Nordson Corporation for $460.00 per share in cash. If you are an Atrion shareholder, click here to learn more about your legal rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT

NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

See News Rankings

Charts implemented using Lightweight Charts™